Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 4
2005 3
2006 3
2007 4
2008 1
2009 2
2011 3
2012 4
2013 1
2014 2
2015 1
2016 1
2017 5
2018 2
2019 3
2020 2
2022 1
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Tuberculosis: the drug development pipeline at a glance.
Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. Villemagne B, et al. Among authors: baulard ar. Eur J Med Chem. 2012 May;51:1-16. doi: 10.1016/j.ejmech.2012.02.033. Epub 2012 Feb 25. Eur J Med Chem. 2012. PMID: 22421275 Review.
Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis.
Pandey S, Vilchèze C, Werngren J, Bainomugisa A, Mansjö M, Groenheit R, Miotto P, Cirillo DM, Coulter C, Baulard AR, Schön T, Jacobs WR Jr, Djaout K, Köser CU. Pandey S, et al. Among authors: baulard ar. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0109623. doi: 10.1128/aac.01096-23. Epub 2023 Dec 1. Antimicrob Agents Chemother. 2024. PMID: 38038476 Free PMC article.
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
Villemagne B, Machelart A, Tran NC, Flipo M, Moune M, Leroux F, Piveteau C, Wohlkönig A, Wintjens R, Li X, Gref R, Brodin P, Deprez B, Baulard AR, Willand N. Villemagne B, et al. Among authors: baulard ar. ACS Infect Dis. 2020 Mar 13;6(3):366-378. doi: 10.1021/acsinfecdis.9b00277. Epub 2020 Mar 2. ACS Infect Dis. 2020. PMID: 32011115
Exploring the Antitubercular Activity of Anthranilic Acid Derivatives: From MabA (FabG1) Inhibition to Intrabacterial Acidification.
Faïon L, Djaout K, Pintiala C, Piveteau C, Leroux F, Biela A, Slupek S, Antoine R, Záhorszká M, Cantrelle FX, Hanoulle X, Korduláková J, Deprez B, Willand N, Baulard AR, Flipo M. Faïon L, et al. Among authors: baulard ar. Pharmaceuticals (Basel). 2023 Feb 22;16(3):335. doi: 10.3390/ph16030335. Pharmaceuticals (Basel). 2023. PMID: 36986435 Free PMC article.
The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis.
Flipo M, Frita R, Bourotte M, Martínez-Martínez MS, Boesche M, Boyle GW, Derimanov G, Drewes G, Gamallo P, Ghidelli-Disse S, Gresham S, Jiménez E, de Mercado J, Pérez-Herrán E, Porras-De Francisco E, Rullas J, Casado P, Leroux F, Piveteau C, Kiass M, Mathys V, Soetaert K, Megalizzi V, Tanina A, Wintjens R, Antoine R, Brodin P, Delorme V, Moune M, Djaout K, Slupek S, Kemmer C, Gitzinger M, Ballell L, Mendoza-Losana A, Lociuro S, Deprez B, Barros-Aguirre D, Remuiñán MJ, Willand N, Baulard AR. Flipo M, et al. Among authors: baulard ar. Sci Transl Med. 2022 May 4;14(643):eaaz6280. doi: 10.1126/scitranslmed.aaz6280. Epub 2022 May 4. Sci Transl Med. 2022. PMID: 35507672
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
Blondiaux N, Moune M, Desroses M, Frita R, Flipo M, Mathys V, Soetaert K, Kiass M, Delorme V, Djaout K, Trebosc V, Kemmer C, Wintjens R, Wohlkönig A, Antoine R, Huot L, Hot D, Coscolla M, Feldmann J, Gagneux S, Locht C, Brodin P, Gitzinger M, Déprez B, Willand N, Baulard AR. Blondiaux N, et al. Among authors: baulard ar. Science. 2017 Mar 17;355(6330):1206-1211. doi: 10.1126/science.aag1006. Epub 2017 Mar 16. Science. 2017. PMID: 28302858
Molecular mapping of lipoarabinomannans on mycobacteria.
Verbelen C, Christiaens N, Alsteens D, Dupres V, Baulard AR, Dufrêne YF. Verbelen C, et al. Among authors: baulard ar. Langmuir. 2009 Apr 21;25(8):4324-7. doi: 10.1021/la900302a. Langmuir. 2009. PMID: 19278203
Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening.
Faïon L, Djaout K, Frita R, Pintiala C, Cantrelle FX, Moune M, Vandeputte A, Bourbiaux K, Piveteau C, Herledan A, Biela A, Leroux F, Kremer L, Blaise M, Tanina A, Wintjens R, Hanoulle X, Déprez B, Willand N, Baulard AR, Flipo M. Faïon L, et al. Among authors: baulard ar. Eur J Med Chem. 2020 Aug 15;200:112440. doi: 10.1016/j.ejmech.2020.112440. Epub 2020 May 18. Eur J Med Chem. 2020. PMID: 32505086 Free article.
A comprehensive analysis of the protein-ligand interactions in crystal structures of Mycobacterium tuberculosis EthR.
Tanina A, Wohlkönig A, Soror SH, Flipo M, Villemagne B, Prevet H, Déprez B, Moune M, Perée H, Meyer F, Baulard AR, Willand N, Wintjens R. Tanina A, et al. Among authors: baulard ar. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):248-258. doi: 10.1016/j.bbapap.2018.12.003. Epub 2018 Dec 13. Biochim Biophys Acta Proteins Proteom. 2019. PMID: 30553830 Free article.
44 results